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Liu et al. demonstrate that adult human
fibroblasts can be efficiently and directly
reprogrammed into highly pure spinal
motor neurons (hiMNs). These neurons
exhibit mature electrophysiology, form
neuromuscular junctions, and control
muscle activity. Interestingly, hiMNs from
ALS fibroblasts show physiological
deficits, which can be ameliorated by a
small chemical compound.
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Subtype-specific neurons obtained from adult hu-
mans will be critical to modeling neurodegenerative
diseases, such as amyotrophic lateral sclerosis
(ALS). Here, we show that adult human skin fibro-
blasts can be directly and efficiently converted into
highly pure motor neurons without passing through
an induced pluripotent stem cell stage. These adult
human induced motor neurons (hiMNs) exhibit the
cytological and electrophysiological features of spi-
nal motor neurons and form functional neuromus-
cular junctions (NMJs) with skeletal muscles. Impor-
tantly, hiMNs converted from ALS patient fibroblasts
show disease-specific degeneration manifested
through poor survival, soma shrinkage, hypoactivity,
and an inability to form NMJs. A chemical screen
revealed that the degenerative features of ALS hiMNs
can be remarkably rescued by the small molecule
kenpaullone. Taken together, our results define a
direct and efficient strategy to obtain disease-rele-
vant neuronal subtypes from adult human patients
and reveal their promising value in disease modeling
and drug identification.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s
disease, is a devastating adult-onset neurological disorder prev-
alent worldwide with no effective cure (Arbab et al., 2014; Glad-
man et al., 2012). ALS is characterized by progressive motor
neuron (MN) dysfunction and death; however, the mechanisms
leading to selective MN loss around the age of onset remain
poorly understood (Arbab et al., 2014; Robberecht and Philips,
2013). This is largely due to the lack of available patient-specific
MNs during disease progression (Arbab et al., 2014). Studies of
post-mortem tissues, as well as transgenic cellular and animal
models, have provided valuable insights into pathogenic ALS
phenotypes (Bruijn et al., 1998; Gurney et al., 1994; Hadzipasic
et al., 2014; Haidet-Phillips et al., 2011; Kiernan and Hudson,C1991; Qiu et al., 2014; Re et al., 2014; Spalloni et al., 2011;
Wada et al., 2012). Nonetheless, major discrepancies and con-
troversies exist in these models owing to genetic, anatomical,
and experimental variations (Bories et al., 2007; Delestre´e
et al., 2014; Haidet-Phillips et al., 2011; Kuo et al., 2004; Leroy
et al., 2014; Re et al., 2014; Saxena et al., 2013). Unsurprisingly,
no therapeutic has succeeded in translation to the clinic (Glad-
man et al., 2012; Musaro`, 2013).
Induced pluripotent stem cells (iPSCs) derived from human
skin fibroblasts and differentiated into spinal MNs are emerging
as a cellular model for investigating ALS (Chen et al., 2014;
Dimos et al., 2008; Kiskinis et al., 2014). This model utilizes
genetic mutation(s) naturally occurring in human patients and
thus avoids potential pitfalls associated with ectopic overex-
pression of mutant genes. New insights into the pathology of
ALS have been gained with this model (Chen et al., 2014;
Kiskinis et al., 2014); however, the generation of iPSCs and
their stepwise differentiation into MNs are lengthy and complex
processes accompanied by technical limitations due to iPSC
line variation and the heterogeneity of differentiated neurons
(Arbab et al., 2014). Furthermore, because iPSCs are reset to
an embryonic stage during reprogramming (Lapasset et al.,
2011; Miller et al., 2013; Rando and Chang, 2012), a major
difficulty with modeling ALS is the induction of an adult-
onset pathology using iPSC-derived fetal stage neurons (Arbab
et al., 2014).
Direct lineage reprogramming bypasses pluripotency and
converts fully differentiated somatic cells into functional neurons
(Pang et al., 2011; Vierbuchen et al., 2010; Yoo et al., 2011). This
technology is also capable of creating subtype-specific neurons,
such as dopaminergic neurons (Caiazzo et al., 2011), striatal me-
dium spiny neurons (Victor et al., 2014), nociceptive neurons
(Wainger et al., 2015), and cholinergic neurons (Liu et al., 2013;
Son et al., 2011). Despite limitations with reprogramming effi-
ciency and neuronal purity, directly converted subtype-specific
neurons are potentially more valuable to disease modeling and
drug identification for late-onset human neurological disorders
(Arbab et al., 2014). As a proof-of-concept study, we provide a
protocol for direct and highly efficient conversion of adult human
fibroblasts to functionally mature MNs with high purity. We
further reveal pathology of MNs derived from ALS patient fibro-
blasts with FUS mutations. Most importantly, a pilot drug screenell Reports 14, 115–128, January 5, 2016 ª2016 The Authors 115
identified a small molecule capable of rescuing key deficits in
these diseased MNs.
RESULTS
Rapid and Efficient Conversion of Adult Human
Fibroblasts to MNs
We previously demonstrated that postnatal and adult human
fibroblasts can be rapidly and efficiently converted to (human
induced) cholinergic neurons (hiCNs) through the synergistic
actions of extrinsic and intrinsic cues (Liu et al., 2013). Howev-
er, these hiCNs lack the expression of ISL1 and LHX3, two fac-
tors essential to the development of MNs (Thaler et al., 2002).
We then examined whether hiCNs can be further specified to a
bona fide MN fate. cDNAs encoding ISL1 and LHX3 were
subcloned into a polycistronic lentiviral vector for expression
at a 1:1 ratio, as this is essential for MN specification (Lee
et al., 2012). Primary fibroblasts (Table S1) from three normal
(NL) healthy adult humans (AG05811, 71 years, designated
NL1; AG07473, 50 years, designated NL2; and AG09969, 53
years, designated NL3) were co-transduced with lentiviruses
expressing NEUROG2-IRES-GFP-T2A-SOX11 and ISL1-T2A-
LHX3 (hereafter referred to as NSIL). Then, 2 days post-viral
infection (dpi), these cells were switched to neuron-induction
media containing our previously identified extrinsic factors,
forskolin (FSK) and dorsomorphin (DM), and basic fibroblast
growth factor (FGF2) (Liu et al., 2013). Neuronal conversion
was monitored daily by live-cell fluorescence microscopy
and analyzed by immunocytochemistry at the indicated time
points.
Remarkably, 86%–96% of NSIL virus-transduced adult fibro-
blasts (indicated by GFP co-expression) were converted to
TUBB3+ neuron-like cells by 14 dpi (Figures 1A and 1B). During
this conversion process, cells rapidly changed their initially flat,
spread-out morphology to one with bipolar and multipolar pro-
cesses. They progressively became more elaborate with round
or pyramidal somas, condensed nuclei, long axons, andmultiple
neurites, as indicated by specific staining with the pan-neuronal
markers MAP2 and NF200 at 21 dpi (Figures 1C and 1D). The
converted cells also expressed the presynaptic marker synapto-
tagmin 1 (SYT1) in a discrete punctate pattern, suggesting the
establishment of synaptic terminals by 21 dpi in culture (Fig-
ure 1E). The inclusion of FSK, DM, and FGF2 in the culture media
is essential for efficient neuronal reprogramming, as omission of
any small molecule or FGF2 greatly reduced the population of
TUBB3+ cells (Figures S1A and S1B).
Immunocytochemistry showed that the reprogrammed
neurons exclusively expressedmarkers for spinalMNs, including
HB9, CHAT, and VACHT (Figures 1A and 1F–1I). Over 84% and
95% of TUBB3+ cells co-stained with HB9 and CHAT, respec-
tively. In sharp contrast, none expressed markers for dopami-
nergic (TH) or GABAergic (GAD67) neurons. These data indicate
that adult human fibroblasts are reprogrammed into spinal (hu-
man induced) MNs (hiMNs). Our qRT-PCR analysis of HOX
gene expression showed that hiMNs are a mixture of cervical
and/or thoracic spinal MNs (Figure S1C).
When co-cultured with mouse astrocytes, hiMNs survived
over 49 dpi, outgrewmultiple long processes, and formed dense116 Cell Reports 14, 115–128, January 5, 2016 ª2016 The Authorsneuronal networks throughout the whole culture (Figure 1J).
Compared to cells at earlier stages (Figures 1A and 1H), the
expression of HB9 was much reduced or diminished by 49 dpi
(Figure 1K), resembling its endogenous expression pattern in
moremature spinal MNs (Detmer et al., 2008). In contrast, hiMNs
maintained strong CHAT expression, indicative of cholinergic
neurotransmitter synthesis (Figure 1K).
Direct Fate Switch without a Progenitor Stage
A time course analysis showed that around 46% and 90% of the
virus-transduced cells expressed the mature neuronal marker
MAP2 at 7 and 10 dpi, respectively (Figure S1D). During this pro-
cess, proliferative neural progenitors were not involved in the
NSIL-mediated conversion of adult human fibroblasts. Cell pro-
liferation was examined by 2-hr pulse labeling with 5-bromo-
deoxyuridine (BrdU) before immunocytochemical analyses at
0, 1, 3, 7, and 10 dpi, respectively (Figures S1D and S1E). The
non-transduced control cells were efficiently BrdU labeled under
this condition. However, none of the converted MAP2+ cells
incorporated BrdU when pulsed at 7 or 10 dpi (Figures S1D
and S1E). BrdU incorporation appeared to be nontoxic to con-
verted neurons, as a majority could be labeled by BrdU if the
proliferating fibroblasts were initially treated with BrdU 2 hr
before lentiviral infection (Figures S1D and S1E). The neural pro-
genitor markers SOX2 and OLIG2 were never detected during
the early reprogramming process (Figure S1F). As controls,
SOX2 and OLIG2 also failed to induce any neuronal conversion
of human fibroblasts. Together, these data indicate that adult hu-
man fibroblasts are directly and efficiently reprogrammed to
highly pure hiMNs under a defined culture condition.
Functional Maturation of hiMNs
The electrophysiological properties of hiMNs were determined
by whole-cell patch-clamp recordings. All the recorded hiMNs
reprogrammed from normal adult human fibroblasts fired repet-
itive action potentials (APs) upon current injection when exam-
ined at 49 dpi or beyond (Figure 2A). In voltage-clamp mode,
hiMNs showed tetrodotoxin (TTX)-sensitive inward currents,
indicating sodium current influx through voltage-gated sodium
channels (Figures 2B and 2C). These channels have stereotypi-
cal fast activation and slow inactivation characteristics (Figures
2C and 2D). The hiMNs converted from all healthy human patient
fibroblasts exhibited similar excitability, including AP firing
threshold, frequency, half-width, amplitude, and the delay of
the first spike (Figures 2E–2I). There were also no major differ-
ences in channel properties among these hiMNs, as measured
approximately by sodium and potassium current amplitudes
(Figures 2J–2L and S2). GABA, glycine, and glutamate receptors
on hiMNs could be activated by puffs of their respective ago-
nists. This illustrates the presence of both functional inhibitory
and excitatory postsynaptic receptors on reprogrammed hiMNs
(Figure 2M). Robust spontaneous postsynaptic currents (sPSCs)
could be detected when hiMNs were co-cultured with mouse
cortical neurons, indicating functional synapse formation be-
tween these neuron populations (Figure 2N; n = 23; 0.266 ±
0.104 Hz and 13.034 ± 3.522 pA for average frequency and
amplitude, respectively). Together, these data demonstrate
that hiMNs become electrophysiologically mature.
Figure 1. Rapid and Efficient Conversion of
Adult Human Fibroblasts to hiMNs
(A) Neuronal marker expression in adult human
fibroblast (NL1)-derived hiMNs at 14 days post-
infection (dpi). The virus-transduced cells are
indicated by GFP fluorescence. Scale bar, 50 mm.
(B) Reprogramming efficiency determined by
TUBB3 expression at 14 dpi is shown (mean ±
SEM, n = 3 independent samples, 20 randomly
selected 203 fields per sample were examined).
(C–E) Immunofluorescent visualization of the indi-
cated markers in hiMNs at 21 dpi. The punctate-
staining pattern of SYT1 in neuronal processes is
indicated by the arrowheads, while the arrow in-
dicates a non-converted cell within the same
image field. Scale bars, 50 mm.
(F and G) Neuronal purity was determined by the
expression of MNmarkers at 21 dpi (mean ± SEM,
n = 3 independent samples with R600 cells in
each group).
(H and I) Immunofluorescent visualization of
marker expression for hiMNs at 21 dpi. The
punctate-staining pattern of CHAT in neuronal
processes is indicated by the arrowheads, while
the arrow indicates a non-converted cell within the
same image field. Scale bars, 50 mm.
(J and K) hiMN morphology and marker expres-
sion at 49 dpi. HB9 expression is significantly
reduced in more mature hiMNs while robust
CHAT expression persists. A marker-negative cell
is indicated by an arrow. Scale bars, 50 mm.
See also Figure S1 and Table S1.A key feature of spinal MNs is their ability to form functional
neuromuscular junctions (NMJs). This was determined through
co-culture of hiMNs and primary mouse skeletal myotubes.
Extensive growth and branching of hiMN axons were observed
3–7 days after co-culture (Figures 3A and 3B). Many axons pro-
jected along multinucleated myotubes, which stained positive
for the mature muscle marker myosin heavy chain (MHC). At
sites of contact with myotubes, the enlarged presynaptic SYN+
axonal terminals of hiMNs frequently aligned with the clustered
postsynaptic acetylcholine receptors, which were specificallyCell Reports 14, 115–12detected by rhodamine-labeled a-bun-
garotoxin (a-BTX) on the muscle surface
(Figure 3B). As controls, acetylcholine
receptor clustering was not observed on
myotubes when cultured alone or with
primary mouse cortical neurons (Figures
3C and 3D). These data suggest that
mature hiMNs uniquely induce the forma-
tion of NMJs with cultured muscles.
Whole-cell patch-clamp recordings
were then performed on co-cultured my-
otubes to determine whether these newly
formed NMJs were functional (Figure 3E).
Robust spontaneous end plate currents
(sEPCs) were detected from myotubes
co-cultured with hiMNs, but not from
those cultured alone or with cortical neu-rons (Figures 3F, S3A, and S3B). These currents could be specif-
ically blocked by wash-in of the acetylcholine receptor antago-
nist (+)-tubocurarine during recordings (Figures 3G, S3C, and
S3D). This confirmed that the observed sEPCs were mediated
by established NMJs. Larger sEPCs also could be eliminated
by blocking neuron-specific voltage-gated sodium channels
with TTX (Figures 3H, S3C, and S3D). Interestingly, smaller
sEPCs could still be observed under this condition, reflecting
TTX-insensitive quantum release of synaptic vesicles from
hiMNs to the co-cultured muscles. In contrast, sEPCs were not8, January 5, 2016 ª2016 The Authors 117
Figure 2. Electrophysiological Properties of hiMNs
(A) Repetitive AP waveforms recorded under current-clamp mode. The precondition sweep and sweeps immediately above threshold and at the highest
frequency are shown in the lower panel.
(B) Representative potassium and TTX-sensitive sodium currents are shown.
(C) A zoomed-in view of TTX-sensitive sodium currents presented in (B) is shown.
(D) A plot of the sodium current (I)-voltage (V) curve is shown.
(E–L) Control hiMNs exhibit comparable electrophysiological properties (mean ± SEM; NL1, n = 21; NL2, n = 7; NL3, n = 6).
(M) Representative electrophysiological responses of hiMNs to puffs of receptor agonists are shown (n = 3 for GABA, n = 2 for glycine, and n = 4 for kainate).
(N) Representative traces of spontaneous postsynaptic currents (sPSCs) recorded from hiMNs are shown.
See also Figure S2 and Table S2.significantly alteredwhenmuscle-specific voltage-gated sodium
channels were inhibited by the antagonist m-connotoxin (Figures
3I, S3C, and S3D). Together, these data reveal that hiMNs func-
tionally innervate co-cultured skeletal muscles and control their
activities through the NMJ formations.
Efficient Conversion of ALSPatient Fibroblasts to hiMNs
We applied the same reprogramming process to skin fibroblasts
derived from three ALS patients aged between 37 and 50 years
(Table S1). These patients were identified to harbor genetic118 Cell Reports 14, 115–128, January 5, 2016 ª2016 The Authorsmutations in the FUS gene, including a synonymous mutation
(c.1566G>A) that does not change the FUSamino acid sequence
(ND29563, 37 years,mutationR522R, designatedALS1) (Lai et al.,
2011); a mutation that alters protein sequence but has no clear
effect on protein subcellular localization (ND39027, 50 years,
mutation H517Q, designated ALS2) (Kwiatkowski et al., 2009);
and a mutation that alters amino acid sequence, resulting in
FUS cytoplasmic translocation (ND40077, 47 years, mutation
R521G, designated ALS3) (Kwiatkowski et al., 2009). ALS pa-
tient-derived fibroblasts could be efficiently reprogrammed into
Figure 3. hiMNs Induce Functional NMJs
(A and B) Immunofluorescent visualization of
typical neuromuscular junctions (NMJs, indicated
by arrows) that formed between hiMNs and pri-
mary mouse myotubes in co-culture are shown.
Scale bars, 50 (A) and 10 mm (B).
(C and D) NMJs were not detectable when my-
otubes were cultured alone (C) or with cortical
neurons (D). Scale bars, 10 mm.
(E) A typical image shows a glass pipette-patched
myotube in culture.
(F) Spontaneous end plate currents (sEPCs) were
detected in myotubes when co-cultured with
hiMNs (n = 36), but not when cultured alone (n = 9)
or with cortical neurons (n = 13).
(G) sEPCs are sensitive to the acetylcholine re-
ceptor antagonist (+)-tubocurarine (n = 4).
(H) sEPCs are sensitive to treatment with tetro-
dotoxin (TTX), a specific inhibitor of voltage-gated
sodium channels in neurons (n = 6). Miniature TTX-
insensitive currents were still detectable.
(I) sEPCs are insensitive to treatment with m-con-
notoxin, a specific inhibitor of voltage-dependent
sodium channels in muscles (n = 3).
See also Figure S3.neurons with 80%–93% of surviving NSIL-transduced cells
expressing TUBB3 by 14 dpi (Figures 4A and 4B). The converted
cells also expressed the pan-neuronal markers MAP2 and
NF200, as well as the presynaptic marker SYT1, by 21 dpi (Fig-Cell Reports 14, 115–12ures 4C–4E). These cells displayed
typical MN morphology with multiple
dendrites and prominent axon. Immuno-
cytochemistry further revealed that 84%–
87% and 95%–97% of TUBB3+ cells
co-stained for HB9 and CHAT, respec-
tively (Figures 4F–4I). Together, these
data demonstrate that fibroblasts derived
from adult ALS patients can be efficiently
converted to highly pure hiMNs, hereby
referred to as ALS hiMNs. These data
also indicate that FUS mutations do not
impede neuronal reprogramming of adult
patient fibroblasts, which is consistent
with the fact that neuronal development
is not obviously altered in these patients.
Mislocalization of FUS inALShiMNs
Cytoplasmic retention of the mutated
FUS protein is a major pathological
feature identified in spinal MNs of ALS
patients (Kwiatkowski et al., 2009; Vance
et al., 2009). As such, we examined the
expression and subcellular localization
of FUS protein in fibroblasts and hiMNs.
Western blot analysis did not reveal
any significant difference on the level of
endogenous FUS in fibroblasts obtained
from both ALS patients and healthy con-trols (Figure 5A). Immunocytochemistry showed a predominant
nuclear distribution of endogenous FUS but failed to detect a
major difference between these fibroblast lines (Figure 5B). In
sharp contrast, the subcellular distribution of FUS protein was8, January 5, 2016 ª2016 The Authors 119
Figure 4. hiMNs Converted from Fibro-
blasts of Adult Human ALS Patients
(A) Neuronal conversion of fibroblasts from human
ALS patients. Virus-transduced cells are indicated
by GFP fluorescence. Scale bar, 50 mm.
(B) Conversion efficiency as determined by TUBB3
expression at 14 dpi is shown (mean ± SEM, n = 3
independent samples, 20 randomly selected 203
fields per sample were examined).
(C–E) Immunofluorescent visualization of neuronal
marker expression in converted cells from ALS
patients. Arrows show marker-negative cells.
Scale bars, 50 mm.
(F and G) Reprogrammed neurons from ALS pa-
tients express markers for spinal MNs. Arrows
show marker-negative cells. Scale bars, 50 mm.
(H and I) Neuronal purity was determined by
expression of MNmarkers at 21 dpi (mean ± SEM,
n = 3 independent samples with R600 cells
counted for each group).
See also Table S1.significantly different when these fibroblasts were converted to
hiMNs. Compared to normal controls, a larger fraction of endog-
enous FUS was mislocated into the cytoplasm of ALS hiMNs
(Figures 5C and 5D), consistent with post-mortem analysis of
spinal MNs from ALS patients with mutant FUS (Kwiatkowski
et al., 2009; Vance et al., 2009).
Given that amino acid sequence is not altered in the synony-
mous c.1566G > A FUSmutant (ALS1 patient), its mislocalization
was somewhat unexpected; however, itmaynot be totally surpris-
ing. A synonymousmutation in the multidrug resistance 1 (MDR1)
gene was shown to affect the timing of co-translational folding
and, therefore, toalter the structureof substrateand inhibitor inter-
action sites (Kimchi-Sarfaty et al., 2007). Recent studies also
confirmed that synonymous codons have a huge influence on
the rate of translation elongation and subsequent protein folding,
structure, and function (Yu et al., 2015; Zhou et al., 2013, 2015).
Althoughsystematicstudiesare required todeterminehowsynon-
ymous c.1566G > A mutation leads to the mislocalization of FUS
protein, it is highlypossible that thismutation results in alteredpro-120 Cell Reports 14, 115–128, January 5, 2016 ª2016 The Authorstein folding and structure. Of note, the
c.1566G>Avariant frequentlywasassoci-
ated with ALS patients (Lai et al., 2011),
although it also was detected in certain
control samples (Corrado et al., 2010). It
would be interesting to determine whether
the control samples with this synonymous
mutation eventually develop ALS at a later
stage. Notwithstanding, other genetic and
non-genetic causes are not excluded for
ALS patientswith synonymous FUSmuta-
tions. TheALS1patientmaywell represent
a sporadic case.
Morphological and Survival Deficits
of ALS hiMNs
A hallmark of ALS is the progressive
degeneration and loss of MNs (Clevelandand Rothstein, 2001; Pasinelli and Brown, 2006). We examined
cell morphology and survival of hiMNs co-cultured with wild-
type mouse astrocytes. ALS hiMNs exhibited shrunken somas
with sizes ranging from 198 to 247 mm2 at 49 dpi. This is signifi-
cantly smaller than hiMNs derived from age-matched healthy
controls, which had soma sizes ranging from 292 to 330 mm2
(Figures 6A–6C). Shrinkage of spinal MN somas has been
observed in post-mortem human ALS patients and is believed
to precede neuronal death (Kiernan and Hudson, 1991).
In contrast to the similar survival rates among all normal
hiMNs, ALS hiMNs were more susceptible to death with survival
rates of 45%–65%, 9%–48%, and 8%–37% relative to normal
hiMNs when examined at 21, 35, and 49 dpi, respectively (Fig-
ure 6D). To ascertain whether these survival deficits can be
caused by mutations in FUS, we transduced normal healthy fi-
broblasts (NL1) with virus expressing ALS patient-specific FUS
mutants. These ectopic mutant proteins either have a predomi-
nant nuclear localization similar to wild-type FUS (H517Q) or
are diffusedly localized in the cell (R514G, R521C, and R522G;
Figure 5. Mislocalization of FUS in ALS
hiMNs
(A) Western blot analysis of FUS expression in
fibroblasts is shown.
(B) Confocal images show subcellular distribution
of FUS in fibroblasts. Scale bars, 50 mm.
(C) Expression and distribution of FUS in hiMNs.
The nucleus and soma are outlined with white and
green lines, respectively. The arrow indicates
complete nuclear exclusion of FUS in some dying
ALS1 hiMNs. Scale bars, 10 mm.
(D) Quantification of subcellular FUS distribution in
hiMNs (mean ± SEM, n = 50 cells from three in-
dependent samples for each group, **p = 0.005).Figure S4A). Western blot analysis showed a comparable
expression of ectopic and endogenous FUS (Figures S4B and
S4C). Compared to normal healthy cells transduced with either
an empty or wild-type FUS virus, hiMNs converted from FUS
mutant virus-transduced normal fibroblasts showed a significant
reduction in survival when examined at 21 dpi (Figure 6E), reca-
pitulating the deficits observed in ALS hiMNs. Together, the
morphological and survival deficits of ALS hiMNs match those
pathological phenotypes detected in post-mortem tissues
(Kiernan and Hudson, 1991), animal ALS models (Hadzipasic
et al., 2014; Qiu et al., 2014), and iPSC-derived MN models (Kis-
kinis et al., 2014).
Electrophysiological Deficits of ALS hiMNs
The electrophysiological properties of ALS hiMNs derived from
ALS1 and ALS2 patients were examined in detail at 49 dpi and
beyond. ALS1 and ALS2 hiMNs were representative of the
survival extremes among reprogrammed ALS hiMNs (Figure 6D).
Whole-cell patch-clamp recordings showed that ALS hiMNs,
similar to normal controls, exhibited typical inward sodium
currents and outward potassium currents (Figures S5A–S5C),
suggesting that they acquired basic neuronal properties. The
amplitudes of sodium and potassium currents were compara-
ble, although the normalized values by membrane capacitance
were much reduced for ALS hiMNs (Figures S5D and S5E).
Most interestingly, ALS hiMNs showed dramatic deficits in AP
firing (Figure 6F). Unlike control hiMNs that could fire repetitive
APs at later culture time points, the ALS hiMNs fired very infre-
quently at all the time points examined (Figure S5F). Statistical
analyses showed that the threshold, frequency, amplitude,
and half-width of APs, as well as delay of the first spike, were
significantly different between normal and ALS hiMNs (Figures
6G–6K).Cell Reports 14, 115–12Furthermore, synaptic connectivity was
investigated in co-culture. When acting
as the postsynaptic neuron in co-culture
with mouse cortical neurons, normal and
ALS hiMNs showed comparable sPSC
frequency and amplitude, suggesting
that ALS hiMNs formed normal synapses
with presynaptic neurons and received in-
puts from these cells (Figures 6L–6N). The
presynaptic functionality of ALS hiMNsand NMJ formation were examined in co-culture with primary
mouse skeletal muscles. Compared to normal hiMNs, ALS
hiMNs rarely induced NMJ formation (Figures 6O and 6P).
Consistent with this morphological deficit, whole-cell patch-
clamp recordings performed on muscles showed that sEPCs
were not or rarely detected when co-cultured with ALS hiMNs,
revealing profound dysfunction in the ability of these diseased
MNs to control muscle contraction (Figures 6Q–6S).
A Screen of Small Molecules Aiming to Promote ALS
hiMN Survival
We observed that hiMNs are sensitive to systemic stress
induced by a replating procedure during culture. Over 80% of
ALS1 hiMNs died 3 days post-replating on matrigel/laminin-
coated culture vessels at 14 dpi (Figure S6A). Co-culture with pri-
mary mouse astrocytes also led to over 60% death of these cells
7 days after replating. Using this stress-accelerated cell death
model, we performed a pilot screen of small molecules that pro-
mote the survival of ALS hiMNs. These candidates included
valproic acid (VPA) (Leng et al., 2008; Niu et al., 2013), isoxazole
(ISX) (Ryan et al., 2013), lithium chloride (LiCl) (Leng et al., 2008),
kenpaullone (Ken) (Yang et al., 2013), and an aminopropyl carba-
zole derivative (P7C3) (Pieper et al., 2010), which are known to
promote neuronal survival. Consistently, the survival of ALS1
hiMNs on matrigel/laminin-coated plates was enhanced by
each of these candidate molecules at an appropriate concen-
tration, though the effect of Ken was modestly superior (Fig-
ure S6B). We then reexamined these molecules on ALS1 hiMNs
that were replated on astrocyte-coated plates. Interestingly, Ken
was the most effective at promoting the survival of these cells,
while the remaining chemicals were not as effective under this
culture condition (Figure S6C). A binary combination of these
chemicals did not outperform Ken alone. A dosage analysis8, January 5, 2016 ª2016 The Authors 121
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showed that the optimal concentration for Ken was 1 mM, while
concentrations higher than 5 mM can result in chemical precipi-
tation and loss of the protective effect (Figures S6D and S6E).
Functional Rescue of ALS hiMNs by Ken
The effect of Ken was further evaluated on ALS hiMNs derived
from all three FUS patients and co-cultured with astrocytes.
Compared to vehicle controls, Ken greatly enhanced the
outgrowth and branching of neuronal processes at all the time
points examined (Figures 7A and 7B). Ken-treated ALS hiMNs
formed a super-dense neuronal network more evident at 35
dpi and thereafter (Figure 7A). These cells also had larger somas,
which were quantified by measuring randomly chosen cells from
triplicate experiments (Figure 7C). There was an average 1.43- to
1.94-fold increase of soma size for Ken-treated ALS hiMNs
when compared to their respective vehicle-treated controls at
49 dpi. A time course analysis revealed a remarkable long-term
effect of Ken on cell survival, with 2.4–4.7 times more Ken-
treated cells surviving relative to vehicle controls when examined
at 49 dpi (Figure 7D). Ken treatment also enabled hiMNs to sur-
vive for months on matrigel/laminin-coated dishes. These cells
formedmassive SYN1+/TUBB3+ neuronal networks (Figure S6F).
Together, these data clearly indicate that the morphological and
survival deficits of ALS hiMNs are greatly improved by the small
molecule Ken.
We then determined whether Ken treatment also ameliorated
the profound electrophysiological defects shown by ALS hiMNs
(Figures 6F–6S). Normal and ALS hiMNs were treated with Ken
starting at 14 dpi and examined by whole-cell patch-clamp re-
cordings at 49 dpi or later. Compared to vehicle-treated ALS
hiMNs, which were hypoactive and rarely exhibited multiple
APs (Figure 6F), Ken-treated ALS hiMNs fired repetitively in a
manner similar to control hiMNs, suggesting the restoration of
normal excitability (Figure 7E). Statistical quantification revealed
a remarkable rescue of ALS hiMNs by Ken in all aspects of elec-
trophysiological properties, including AP threshold, frequency,
amplitude, and half-width, as well as the delay of the first spike
(Figures 7F–7J and S7).
Postsynaptic activities were examined by co-culturing hiMNs
with primary mouse cortical neurons. Robust sPSCs were de-Figure 6. Pathophysiology of ALS hiMNs
(A and B) Representative morphology of hiMNs derived from both normal and
magnification views of hiMNs. Scale bars, 50 mm.
(C) Soma size was measured at 49 dpi (mean ± SEM, n = 3 independent sample
(D) Poor survival of ALS hiMNs at the indicated time points is shown (mean ± SE
(E) Reduced survival of hiMNs converted from normal fibroblasts (NL1) with ect
(mean ± SEM, n = 3 independent samples for each group, ****p < 0.0001).
(F) Representative AP waveforms for the indicated samples. Red and black tra
frequency, respectively.
(G–K) Electrophysiological deficits of ALS hiMNs are shown (mean ± SEM; NL1,
(L) Representative traces of sPSCs recorded from hiMNs co-cultured with cortic
(M and N) Quantification of sPSC frequency and amplitude. No significant differe
ALS1, n = 16; and ALS2, n = 5; n.s., not significant).
(O) Quantification of NMJ frequency is shown (mean ± SEM, n = 3 independent s
****p < 0.0001).
(P) Immunostaining of NMJs is shown (indicated by an arrow). Scale bar, 10 mm.
(Q) sEPCs were recorded from muscles co-cultured with the indicated hiMNs.
(R and S) Quantification of sEPC properties is shown (mean ± SEM; NL, n = 36;
See also Figures S4 and S5 and Table S2.
Ctected in all Ken-treated hiMNs and no significant difference
was observed in either frequency or amplitude (Figures 7K–
7M). Interestingly, sPSCs often occurred in bursts, suggesting
activation of hiMNs by a more active neuronal network and
strong synaptic connectivity between hiMNs and the co-cultured
cortical neurons. Presynaptic function of hiMNs was examined
through co-culture with primary mouse skeletal muscles. In
sharp contrast to the dysfunction of vehicle-treated ALS hiMNs
to innervate muscles (Figures 6O and 6P), Ken treatment
enabled these hiMNs to induce NMJs with a comparable fre-
quency to that of normal hiMNs (Figures 7N and 7O). Patch-
clamp recordings on myotubes co-cultured with ALS hiMNs
showed similar sEPCs as those co-cultured with the normal
healthy hiMNs (Figures 7P–7R). Taken together, these data
demonstrate that Ken treatment is able to robustly rescue ALS
hiMN dysfunction.
DISCUSSION
Analysis of human post-mortem tissues reveals that the degen-
eration and death of MNs are the pathological basis for human
ALS (Kwiatkowski et al., 2009; Vance et al., 2009). However,
one paramount challenge studying this neurodegenerative dis-
ease is the lack of a model system for human patient-specific
MNs. As such, transgenic cellular and animal models tradition-
ally have been employed (Bruijn et al., 1998; Gurney et al.,
1994; Howland et al., 2002; Qiu et al., 2014; Rosen, 1993; Sreed-
haran et al., 2008;Wada et al., 2012). Although important insights
into the pathogenesis of ALS were garnered, the genetic and
anatomical differences between these models and human pa-
tient MNs inevitably raised critical concerns as to artifacts intrin-
sically associated with these non-natural transgenic models
(Bergemalm et al., 2006; Julien and Kriz, 2006; Kiskinis et al.,
2014). A recent cellular model with iPSC-derived MNs overcame
many of these concerns, as these cells inherited all the natural
genetic variations linked to ALS pathology (Arbab et al., 2014;
Chen et al., 2014; Dimos et al., 2008; Kiskinis et al., 2014). Never-
theless, iPSC-differentiated neurons remain at an embryonic
stage (Lapasset et al., 2011; Miller et al., 2013; Rando and
Chang, 2012), and it is uncertain whether the defects identifiedFUS patients at the indicated time points in culture. Images in (B) are higher
s withR150 neurons analyzed for each group, ***p < 0.001).
M, n = 3 independent samples for each group, ****p < 0.0001).
opic expression of the indicated FUS mutants. Cells were counted at 21 dpi
ces represent the AP immediately above threshold and firing at the highest
n = 21; ALS1, n = 28; ALS2, n = 8; **p < 0.01, ***p < 0.001, and ****p < 0.0001).
al neurons are shown.
nces were found between the indicated samples (mean ± SEM; NL1, n = 17;
amples with 300 hiMN network-associated myotubes counted for each group,
ALS1, n = 12; ALS2, n = 6; ****p < 0.0001).
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in these young neurons resemble those of disease-stage degen-
eration in adult human patients (Arbab et al., 2014). Our hiMN-
based cellular model is complementary to the above ALS
models. Parallel to iPSC-derived MNs, hiMNs harbor all the
ALS-causing genetic abnormalities in human patients; yet, these
cells bypass an immature embryonic stage through direct line-
age reprogramming that is absent of pluripotency and stem
cell proliferation (Caiazzo et al., 2011; Pang et al., 2011; Vierbu-
chen et al., 2010; Yoo et al., 2011). Accordingly, hiMNs may
maintain age-dependent features of their parental adult cell
sources, which will be critical to understanding adult-onset neu-
rodegeneration. Thorough investigations in the future will pro-
vide more insights into the effect of direct lineage reprogram-
ming on cell aging and neurodegeneration.
ALS hiMNs exhibit hallmarks of disease-stage degenerative
MNs, including poor survival, soma shrinkage, hypoactivity,
and the lack of muscle control. These deficits have been
observed previously in human patient samples (Kiernan and
Hudson, 1991), transgenic cellular and animal models (Bruijn
et al., 1998; Gurney et al., 1994; Hadzipasic et al., 2014; Hai-
det-Phillips et al., 2011; Qiu et al., 2014; Re et al., 2014; Wada
et al., 2012), and iPSC-derived MNs (Chen et al., 2014; Devlin
et al., 2015; Kiskinis et al., 2014). Further, these hallmarks vali-
date our hiMN-based cellular model for neurodegeneration.
Nonetheless, the hypoexcitability shown by ALS hiMNs is incon-
sistent with the predominant excitotoxicity theory for ALS.
According to this theory, the degeneration and death of patient
MNs are primarily caused by their intrinsic hyperexcitability
(Cleveland and Rothstein, 2001; Kuo et al., 2004; Pasinelli and
Brown, 2006; Wainger et al., 2014). However, this theory is not
without contradictory evidence. It was shown recently that
MNs in amutant superoxide dismutase 1 (mSOD1) mousemodel
of ALS are on average not hyperexcitable prior to disease onset
(Delestre´e et al., 2014). Leroy et al. (2014) also demonstrated
that ALS-resistant, but not the ALS-vulnerable, MNs are hyper-
excitable in mSOD1mice, suggesting that early hyperexcitability
is not an indicator of MN degeneration. Consistent with the
pathology shown by our ALS hiMNs, some of the degenerating
MNs in the mSOD1 mouse model are rather hypoexcitable
(Bories et al., 2007; Delestre´e et al., 2014). Most interestingly,
increasing neuronal excitability is neuroprotective and amelio-
rates MN pathology in mSOD1mice (Saxena et al., 2013). There-
fore, hypoexcitability of affected MNs in ALS may represent a
broad disease-stage endophenotype that could be targeted
for therapy.Figure 7. Kenpaullone Rescues Pathophysiology of ALS hiMNs
(A and B) Kenpaullone (Ken) partially restored morphological deficits of ALS hiMN
50 mm.
(C and D) Ken promoted soma size and survival of ALS hiMNs (mean ± SEM, n =
0.0001).
(E) Representative AP waveforms of the indicated hiMNs treated with Ken are sh
(F–J) Ken treatment normalized electrophysiological properties of ALS hiMNs (m
(K–M) Ken enhanced sPSCs recorded from hiMNs (mean ± SEM; NL1, n = 11; A
(N and O) Ken fully rescued the ability of ALS hiMNs to form NMJs (indicated by ar
300 hiMN network-associated myotubes counted for each group; n.s., not signifi
(P–R) Ken enhanced sEPCs recorded from myotubes co-cultured with the indic
significant; **p < 0.01 when compared ALS1 and ALS2).
See also Figures S6 and S7 and Table S2.
COur proof-of-concept study suggests that adult patient-spe-
cific hiMNs can be employed for drug identification and valida-
tion. ALS hiMNs are especially sensitive to systemic stresses
induced by a replating procedure during culture. Significant
death of hiMNs is robustly detectable within a few days under
these culture conditions with or without supporting astrocytes,
although co-culture with astrocytes may represent a better sys-
tem that emulates an endogenous survival-promoting microen-
vironment for hiMNs. A pilot screen of candidate small chemical
compounds identified that Ken can significantly promote ALS
hiMN survival, in agreement with its previously reported neuro-
protective role (Yang et al., 2013). Our further analysis also
showed that Ken treatment significantly enhances dendritic
outgrowth and rescues soma size of ALS hiMNs. Most impor-
tantly, our whole-cell patch-clamp recordings reveal that Ken
can completely normalize ALS hiMN excitability and restore
the ability to form NMJs and control muscle activity. Notwith-
standing, one unsettling caveat of using Ken as a potential
therapeutic drug is that hiMNs seem to be addicted to Ken treat-
ment, such that these cells wither quickly upon drug withdrawal.
Future research will be required to understand Ken-induced
signaling pathways that may be specifically targeted for therapy.
In conclusion, the results of this study demonstrate that adult
human skin fibroblasts can be directly and efficiently converted
into highly pure and functional hiMNs through a synergistic inter-
action between small molecules and transcription factors. Most
intriguingly, hiMNs converted from adult fibroblasts of ALS pa-
tients with FUS mutations exhibit disease-stage degenerative
features that can be greatly ameliorated by the small molecule
Ken. These findings reveal a unique model system that can be
further exploited for understanding the molecular mechanism
and the identification of therapeutics for human ALS.EXPERIMENTAL PROCEDURES
Animals
Wild-type C57BL/6J mice were purchased from the Jackson Laboratory. All
mice were housed under a 12 hr light/dark cycle and had ad libitum access
to food and water in a controlled animal facility. Experimental protocols were
approved by the Institutional Animal Care and Use Committee at University
of Texas Southwestern.
Plasmid Construction and Virus Production
A third-generation lentiviral vector (pCSC-SP-PW-IRES-GFP) was used to ex-
press NEUROG2-IRES-GFP-T2A-SOX11, NEUROG2-IRES-SOX11, and ISL1-
T2A-LHX3. YFP fusion of wild-type FUS or FUS mutants (R514G, H517Q,s. Representative images were taken at the indicated time points. Scale bars,
3 independent samples withR150 neurons analyzed for each group, ****p <
own.
ean ± SEM; NL1, n = 8; ALS1, n = 19; ALS2, n = 8; n.s., not significant).
LS1, n = 17; ALS2, n = 7; n.s., not significant).
rows) on co-cultured myotubes (mean ± SEM; n = 3 independent samples with
cant). Scale bar, 10 mm.
ated hiMNs (mean ± SEM; NL1, n = 8; ALS1, n = 21; ALS2, n = 10; n.s., not
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R521C, or R522G) were gifts from Aaron Gitler (Addgene plasmid) (Sun et al.,
2011) and individually sub-cloned into the pCSC-SP-PW-IRES-GFP vector by
replacing the IRES-GFP cDNA fragment. Replication-incompetent lentivi-
ruses were produced in HEK293 cells (ATCC) and stored at 4C prior to cell
transduction.
Human Fibroblast Culture
All human patient fibroblasts were obtained from the Coriell Institute for
Medical Research (Table S1). They were maintained in fibroblast medium
(DMEM supplemented with 15% fetal bovine serum and penicillin/strepto-
mycin) at 37C and 5% CO2.
Neuron Induction and Culture
Direct lineage reprogrammingwas conducted according to aprevious protocol
with somemodifications (Liu et al., 2013). In brief, fibroblastswere seeded onto
Matrigel-coated culture vessels (4.8 3 105 per 24- or 48-well plate or 3 3 105
per 6-cm dish) with or without glass coverslips. Cells were transduced the
next day with lentiviral supernatants in the presence of 6 mg/ml polybrene.
Fibroblast culture medium was refreshed after overnight incubation. Then,
1 day later, these cells were switched to C2 medium supplemented with
10 mMFSK (Sigma-Aldrich), 1 mMDM (EMDMillipore), and 10 ng/ml FGF2 (Pe-
proTech). The C2 medium was composed of DMEM:F12:neurobasal (2:2:1),
0.8% N2 (Invitrogen), 0.8% B27 (Invitrogen), and penicillin/streptomycin. The
supplementedC2mediumwashalf changed every other day until 14 dpi. These
cells were either directly used for analysis or further cultured after a replating
procedure (Liu et al., 2013). In brief, cells were dissociated with 0.025% trypsin
for 7 min at 37C and resuspended in FBS-containing fibroblast medium to
quench trypsin activity. This cell suspension was then plated onto a gelatin-
coated culture dish to which fibroblasts tightly attached. About 30 min later,
floating cells, which mainly consisted of induced neurons, were replated onto
anewcoateddish to remove residual fibroblasts, or theyweredirectly collected
by centrifugation at 5003 g for 2min. Cells were resuspended into C2medium
and centrifuged again to remove cell debris. Finally, hiMNs were plated onto
coated culture vessels in C2 medium supplemented with 5 mM FSK and
10 ng/ml each of BDNF, GDNF, and NT3 (PeproTech). Unless indicated other-
wise, C2 media with neurotrophic factors were half changed twice a week.
Immunofluorescence, BrdU Labeling, and Cell Counting
Cell cultures at the indicated time points were fixedwith 4%paraformaldehyde
(PFA) in PBS for 15 min at room temperature, and they were permeabilized/
blocked for 1 hr in blocking solution (13 PBS containing 0.2% Triton X-100
and 3% BSA). Cells were then processed for immunocytochemistry as previ-
ously described (Liu et al., 2013). For subcellular distribution of FUS, confocal
images were obtained with a NIKON A1R Confocal Microscope. The total fluo-
rescence intensity of FUS staining in the nucleus or somawas quantified sepa-
rately using ImageJ with a plugin of ND to Image6D. The cytosolic FUS staining
was calculated by subtracting nuclear fluorescence intensity from that of
the soma. The relative subcellular distribution of FUS was expressed as the
ratio of nuclear/cytoplasmic fluorescence intensity. For experimental details,
please see the Supplemental Experimental Procedures.
Western Blot Analysis
Whole-cell lysates were obtained through direct lysis of cells in 50mMTris-HCl
buffer (pH 8.0) containing 150 mM NaCl, 1% NP40, 1% Triton X-100, 0.1%
SDS, 0.5% sodium deoxycholate, and protease inhibitor cocktail (Roche).
Equal amounts of these lysates (20 mg per lane) were used for SDS-PAGE
and western blot analysis as previously described (Kwiatkowski et al., 2009).
The blots were probed with either a goat anti-FUS (Bethyl Laboratories,
1:5,000) or a mouse anti-actin (Jackson Laboratory, 1:10,000) antibody, fol-
lowed by their corresponding HRP-conjugated secondary antibodies. After
visualizationwith the ECL substrate, densitometric analysis was performed us-
ing the ImageJ software. The relative expression of ectopic and endogenous
FUS proteins was obtained after normalizing to the loading control actin.
Survival and Morphometric Analysis
The hiMNs co-cultured with primary mouse astrocytes were used for these an-
alyses. Cortical astrocytes were prepared from post-natal day (P)1–P3 mouse126 Cell Reports 14, 115–128, January 5, 2016 ª2016 The Authorspups as previously described (Vierbuchen et al., 2010). Endogenous mouse
neurons were removed by vigorous shaking and a few cycles of passaging,
freezing, thawing, and plating. The hiMNs at 14 dpi were replated on astro-
cyte-coated 96-well plates (for survival analysis) or coverslip-containing
24-well plates (for soma size analysis). Co-cultures were fed twice a week
with C2 medium containing 5 mM FSK and 10 ng/ml each of BDNF, GDNF,
and NT3. Cells were fixed and immunostained for TUBB3 and GFP at the indi-
cated time points. Under an AMG EVOS digital inverted fluorescence micro-
scope, TUBB3+GFP+ cells within the entire well of a 96-well plate in triplicate
were manually quantified by a researcher blinded to experimental groups.
Cell counts were normalized to the starting number of cells plated into each
well. To determine the survival rate, a similar number of starting cells were
plated and counted at 14, 21, 35, and 49 dpi. Survival rate at 14 dpi for each
line was set as 100%, to which the subsequent survived cells at each time
point were normalized. To facilitate comparison between different lines, a
relative survival rate was calculated by further normalization to NL1 at each
time point.
The hiMNs on glass coverslips were used for measuring soma size.
TUBB3+GFP+ cells from triplicate samples were randomly selected and
imaged with an Olympus BX51 Microscope equipped with StereoInvestigator
software. Soma area was outlined and measured with the vendor-provided
software. For experiments with ectopic FUS expression, a plasmid without
the GFP tag NEUROG2-IRES-SOX1 was used for reprogramming. As such,
only YFP (empty vector) or YFP-tagged wild-type or mutant FUS was
measured. A similar number of YFP-expressing cells were plated and counted
at 14 and 21 dpi. A survival rate was obtained by normalizing the cell number at
21 dpi to that at 14 dpi. This was further normalized to the empty vector control
group (Vector) to facilitate comparisons between groups.
Neuron and Muscle Co-cultures
Primary skeletal myoblasts from P0–P1 mouse pups were isolated and differ-
entiated into myotubes as previously described with modifications (Nelson
et al., 2013). Briefly, neonatal limb muscles were collected into ice-cold
HBSS under a dissecting microscope and digested with 0.2% collagenase II
and 1,000 U/ml DNase I for 45 min at 37C. Dissociated myoblasts were
expanded in 1% gelatin-coated dishes for 2–4 days in culture medium
(DMEM containing 10% horse serum, 5% newborn calf serum, and 1% chick
embryo extracts), and then they were induced to form multinucleated myo-
tubes by switching to differentiation medium (DMEM containing 2% horse
serum). Then, 24 hr later, 10 mM cytosine arabinoside (AraC) was added
to the culture medium to stop proliferation of undifferentiated cells. After
another day, the cells were dissociated with 0.05% trypsin for 5 min at
37C. Trypsin was inhibited by adding culture medium and removed by centri-
fugation at 5003 g for 2 min. The myotubes were resuspended in C2 medium
containing 10 ng/ml each of BDNF, GDNF, and NT3, and then they were plated
onto coverslips covered with astrocytes and hiMNs at 46 to 49 dpi. A majority
ofmyotubes started rhythmic contractions 2–3 days in co-cultureswith hiMNs.
These cells at 4–7 days in co-culture were used for examination of NMJs and
electrophysiology. NMJs were visualized by confocal laser-scanning micro-
scopy after labeling with rhodamine-conjugated a-BTX (Invitrogen, 1:500)
and immunostaining of TUBB3 (Covance, 1:5,000), synapsin1 (Cell Signaling
Technology, 1:500), and MHC (Sigma, 1:1,000). NMJ formation frequency
was determined by the number of NMJs on >300 myotubes associated with
hiMN networks.
Electrophysiology
Whole-cell patch-clamp recordings were performed under visual guidance us-
ing infra-red differential interference contrast (IR-DIC) and GFP fluorescence,
as previously described (Liu et al., 2013). For experimental details, please
see the Supplemental Experimental Procedures.
Statistical Analysis
All experiments were performed at least twice in triplicate unless otherwise
indicated. Data are presented as mean ± SEM. Statistical analysis was done
in GraphPad Prism. The D’Agostino & Pearson omnibus normality test was first
done on the data to determine whether it was normal distribution. If data
passed the normality test, then one-way or two-way ANOVA was used to
determine significance. If data did not pass the normality test, then the Kru-
shal-Wallis test was used to determine significance. A two-sample two-sided
Kolmogorov-Smirnov test in R (R Project, Bell Laboratories) was used for cu-
mulative probability analysis. Significant differences are indicated by *p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001.
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